Salud financiera de hoja de balance de Black Diamond Therapeutics
Salud financiera controles de criterios 6/6
Black Diamond Therapeutics tiene un patrimonio de los accionistas total de $97.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $137.9M y $40.5M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$112.68m |
| Patrimonio | US$97.43m |
| Total pasivo | US$40.47m |
| Activos totales | US$137.90m |
Actualizaciones recientes sobre salud financiera
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Oct 30
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 21We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Recent updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Oct 30Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Oct 08Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive
Jun 27Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 21We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11Black Diamond Therapeutics EPS misses by $0.16
May 07We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition
Jan 05Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?
Dec 01
Black Diamond nominates development candidate for glioblastoma program
Nov 20Black Diamond Therapeutics EPS beats by $0.02
Nov 10Black Diamond Therapeutics: One To Watch In Precision Oncology Space
Oct 23Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($115.5M) de BDTX superan a sus pasivos a corto plazo ($20.8M).
Pasivo a largo plazo: Los activos a corto plazo de BDTX ($115.5M) superan a sus pasivos a largo plazo ($19.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BDTX está libre de deudas.
Reducción de la deuda: BDTX no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: BDTX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: BDTX dispone de suficiente cash runway para 1.5 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 19.5% cada año.